首页> 外文期刊>Chinese Journal of Integrated Traditional and Western Medicine >Effects of Composite Xinyi Aerosol on Asthma Related Cytokines in Serum and Sputum of Patients with Bronchial Asthma
【24h】

Effects of Composite Xinyi Aerosol on Asthma Related Cytokines in Serum and Sputum of Patients with Bronchial Asthma

机译:复合信义气雾剂对支气管哮喘患者血清和痰中哮喘相关细胞因子的影响

获取原文
获取原文并翻译 | 示例
           

摘要

Objective: To observe the therapeutic effect of composite Xinyi aerosol (XYA) in treating asthma and its influence on asthma related cytokines in serum and sputum of patients with mild or moderate bronchial asthma. Methods: Sixty patients were divided randomly into the treated group and the control group, 30 in each group. They were treated with XYA and Salbutamol aerosol (SA) respectively by spray inhalation once a day for seven days as one therapeutic course to observe the antiasth-matic effect of the treatment. Changes of lung function and the levels of tumor necrosis factor α (TNF-α), interleukine-2 receptor (IL-2R) and interleukine-8 (IL-8) in serum and sputum were observed before and after treatment using enzyme linked immunosorbent assay (ELISA). Levels of TNF-α, IL-2R andIL-8 in the sputum of part of the patients in the treatment group were also observed. Results: In the treated group, 6 patients had the asthma clinically controlled after treatment, 12 were markedly alleviated, 9 alleviated and 3 remained unchanged, while in the control group, the respective numbers were 4, 6, 15 and 5. The controlled-markedly effective rate of XYA was 60.0% , which was significantly better than that of SA (33. 3%, P<0.05). The one second forced expiratory volume percent (FEV1%) and peek expiratory flow rate (PEFR) improved significantly and the levels of TNF-α, IL-2R and IL-8 in serum decreased noticeably in both groups after treatment (P<0.05 or P<0.01), but the improvement in the treated group was more significant as compared with those in the control group (P<0.05). The levels of TNF-α, IL-2R and IL-8 in sputum considerably lowered also after XYA treatment (P<0.01). Conclusion: XYA could regulate the related cytokines in patients with mild or moderate bronchial asthma, and reduce the releasing of inflammatory factors, which is consistent with the improvement of lung functions, so as to ease the airway inflammation chiefly exhibited as cell infiltration in bronchi.
机译:目的:观察复方信义气雾剂(XYA)治疗哮喘的疗效及其对轻,中度支气管哮喘患者血清和痰中哮喘相关细胞因子的影响。方法:将60例患者随机分为治疗组和对照组,每组30例。将它们分别用XYA和沙丁胺醇气雾剂(SA)进行喷雾治疗,每天一次,持续7天,作为一种治疗过程,以观察该疗法的抗哮喘作用。使用酶联免疫吸附剂治疗前后,观察血清和痰液中肺功能和肿瘤坏死因子α(TNF-α),白细胞介素2受体(IL-2R)和白细胞素-8(IL-8)水平的变化。分析(ELISA)。观察治疗组部分患者痰液中TNF-α,IL-2R和IL-8的水平。结果:在治疗组中,有6例患者在治疗后获得了临床控制的哮喘,其中12例显着缓解,9例缓解,3例保持不变,而对照组则分别为4、6、15和5。 XYA的有效率为60.0%,明显优于SA(33。3%,P <0.05)。治疗后两组患者的一秒强迫呼气量百分比(FEV1%)和窥视呼气流速(PEFR)均显着改善,并且血清中TNF-α,IL-2R和IL-8的水平明显降低(P <0.05 P <0.01),但与对照组相比,治疗组的改善更为显着(P <0.05)。 XYA治疗后,痰中TNF-α,IL-2R和IL-8的水平也明显降低(P <0.01)。结论:XYA可以调节轻度或中度支气管哮喘患者相关细胞因子,减少炎症因子的释放,这与肺功能的改善相一致,从而减轻主要表现为支气管细胞浸润的气道炎症。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号